Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Insights on Advances in Immune Thrombocytopenia

Listen to Keith McCrae, MD, Nichola Cooper, MD, and Rachael Grace, MD, MMSc, provide expert insights on ITP management and address frequently asked questions from a live CCO symposium at ASH 2021 on new and emerging therapeutic options, including special patient populations.
person default
Nichola Cooper, MD
person default
Rachael Grace, MD, MMSc
Keith R. McCrae, MD
Released: February 7, 2022

In this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc, provide expert insights on immune thrombocytopenia management, along with addressing frequently asked questions from a live CCO symposium. Topics include:

  • New and emerging therapeutic options
  • Special patient populations, including children
  • The management of immune thrombocytopenia
  • COVID-19 vaccinations and immune thrombocytopenia

Information on this Educational Activity


Keith R. McCrae, MD

Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA

Keith R. McCrae, MD, has disclosed that he has received consulting fees from Dova Pharmaceuticals, Novartis, Rigel Pharmaceuticals, and Sanofi Genzyme.
Nichola Cooper, MD

Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College
London, United Kingdom

Nichola Cooper, MD, has disclosed that she has received funds for research support from Novartis and Rigel Pharmaceuticals and consulting fees from Amgen, Dova Pharmaceuticals, Grifols, Novartis, Principia, Rigel Pharmaceuticals, Sobi, and UCB.
Rachael Grace, MD, MMSc

Assistant Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA

Rachael Grace, MD, MMSc, has disclosed that she has received funds for research support from Agios, Dova Pharmaceuticals, and Novartis and consulting fees from Principia.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Dova Pharmaceuticals, Inc.
Sanofi Genzyme

Related Content

Gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies

person default Justin Arnall, PharmD, BCOP person default Kayla Douglas, PharmD Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 24, 2022 Expired: May 23, 2023

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings